Drug Monograph

Drug/Drug Class:	**Aminosyn™-RF (isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, arginine, and histidine) injection / Biologic Agent**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Aminosyn™-RF 5.2% is a sulfite-free (an amino acid injection – renal formula) available in 500 ml single-dose containers.
Manufacturer:	Hospira, Inc., Lake Forest, IL 60045 USA
Indications:	Aminosyn-RF 5.2%, Sulfite-Free, (an amino acid injection — renal formula) is indicated only as an adjunct to management of patients with potentially reversible acute renal failure who are unable to eat. When infused with hypertonic dextrose as a source of calories and with added appropriate electrolytes and vitamins, Aminosyn-RF 5.2% is suitable as an intravenous source of protein in a parenteral nutritional regimen for such patients
Costs:	$20 per 500 ml container of Aminosyn-RF™ Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☐ Appropriate Indications ☒ No PA Required

Prepared By: Luke Boehmer Pharm.D.
Date: March 3, 2015